Rocket One Inc. Common Stock (NASDAQ:RKTO) Downgraded to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Rocket One Inc. Common Stock (NASDAQ:RKTO) from a sell rating to a strong sell rating in a research note released on Sunday morning.

Separately, Weiss Ratings downgraded Rocket One Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $5.00.

Rocket One Inc. Common Stock Price Performance

Rocket One Inc. Common Stock stock opened at $0.76 on Friday. Rocket One Inc. Common Stock has a 12 month low of $0.49 and a 12 month high of $2.45. The company has a fifty day moving average price of $0.92 and a two-hundred day moving average price of $0.91. The company has a market cap of $17.05 million, a PE ratio of -0.93 and a beta of 0.96.

Rocket One Inc. Common Stock (NASDAQ:RKTO) last issued its earnings results on Friday, August 14th. The company reported ($0.19) earnings per share for the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Lido Advisors LLC bought a new stake in shares of Rocket One Inc. Common Stock during the third quarter valued at approximately $32,000. Kestra Private Wealth Services LLC bought a new stake in Rocket One Inc. Common Stock during the 3rd quarter valued at $51,000. Geode Capital Management LLC boosted its position in Rocket One Inc. Common Stock by 8.0% during the 2nd quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock worth $143,000 after acquiring an additional 9,071 shares during the period. Virtu Financial LLC bought a new position in shares of Rocket One Inc. Common Stock in the third quarter worth $184,000. Finally, Citadel Advisors LLC bought a new stake in shares of Rocket One Inc. Common Stock during the third quarter valued at about $232,000. Institutional investors own 7.08% of the company’s stock.

Rocket One Inc. Common Stock Company Profile

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.